Research continues on the exciting new compounds for the treatment of Alzheimer’s Disease from the Eli Lily Company.  Some additional information and tidbits on the followup and followthroughs in relation to the medications code named “expedition”  and “expedition2″

Earlier trials suggested VR004 could produce results after only … – Eli Lilly and Company (NYSE LLY) announced it will begin enrolling patients this month in two separate but identical Phase III clinical trials of solanezumab(i), previously referred to as LY2062430, an antiamyloid beta monoclonal antibody being investigated as a potential … The trials, called EXPEDITION and EXPEDITION 2, will each include a treatment period that lasts 18 months and are expected to enroll a total of 2000 patients age 55 and over from 16 countries. …

I Love Earth & Human: <AsiaNet>Lilly Advances Second Alzheimer’s … – EXPEDITION and EXPEDITION 2, will each include a treatment period that lasts 18 months and are expected to enroll a total of 2000 patients age 55 and over from 16 countries. In 2008, Lilly began enrolling patients in two Phase III clinical … Eric Siemers M.D., Medical Director, Alzheimer’s disease research for Eli Lilly and Company. “Biomarker results from a Phase II solanezumab trial give us hope that Lilly is on a path toward a treatment that may slow the rate of …

Nerviano Medical Sciences Receives Approval From the FDA to Enter … – NERVIANO, Italy – The FDA has approved an Investigational New Drug (IND) application by Nerviano Medical Sciences to begin a phase I clinical study with its selective PLK-1 small molecule inhibitor for the treatment of cancer. …

??????????????(LY2062430(Solanezumab)P3??) – ?? … – Eli Lilly and Company – Lilly Advances Second Alzheimer’s Disease Treatment Candidate Into Late-Stage Testing by Launching Two Global Trials. http://newsroom.lilly.com/releasedetail.cfm?ReleaseID=385443 … Patients who are taking currently available symptomatic treatments for Alzheimer’s disease can continue treatment during their participation in the EXPEDITION trials. EXPEDITION will be conducted in Argentina, Brazil, Canada, Japan, and United States. …

Gordon & Doner, P.A. v. Jeffrey Joros – Joros=s first amended original petition alleged that he retained Gordon to represent him in claims against Eli Lilly arising out of injuries involving the drug Zyprexa. Suit was to be filed in multidistrict litigation pending in the … Moki Mac River Expeditions v. Drugg, 221 S.W.3d 569, 574 (Tex. 2007); BMC Software Belgium, N.V. v. Marchand, 83 S.W.3d 789, 794 (Tex. 2002). In reviewing a trial court=s ruling on a special appearance, we examine all of the evidence in …

Dimebon Alzheimer?s Disease

http://www.dimebonalzheimers.com